Jubilant Pharmova Ltd

Jubilant Pharmova maintains a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio of 1.65, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Jubilant Pharmova reports a return on equity (ROE) of 13.42% and a return on assets (ROA) of 6.58%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The company's operating margin is 16.12% (calculated as operating income of 11.66 billion INR divided by revenue of 72.35 billion INR), which is a strong indicator of cost control and pricing power. Geographically, Jubilant Pharmova's revenue is concentrated in India, with a significant portion of its operations and customer base located in the domestic market. The company's exposure to international markets is limited, which may pose a risk in the event of domestic economic or regulatory changes. The company does not disclose specific segment revenues, but its business is primarily focused on pharmaceutical products and related services. Looking at growth, Jubilant Pharmova's revenue for the latest period is 72.35 billion INR. While the company has shown consistent revenue generation, the outlook for the current and next fiscal years is not explicitly provided in the available data. The company's capital expenditure of -11.16 billion INR indicates a reduction in investment in physical assets, which may suggest a shift in strategic focus or a response to market conditions. The company's risk profile includes a medium liquidity risk and a low dilution risk. The risk assessment highlights the negative net cash position as a key flag, which could impact the company's ability to fund operations or pursue growth opportunities without external financing. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. Recent events and disclosures do not indicate any major changes in the company's operations or financial strategy. Analysts have provided a mean price target of 1,277.50 INR, with a median price target of 1,305.00 INR, suggesting a generally positive outlook. The mean recommendation of 1.75 indicates a slight bias toward a buy rating, with three buy recommendations and one strong buy recommendation.